RNAi Therapeutics News and Research

RSS
RNA interference (RNAi) was discovered less than a decade ago and already there are human clinical trials in progress or planned. A major advantage of RNAi versus other anti-sense based approaches for therapeutic applications is that it utilizes cellular machinery that efficiently allows targeting of complementary transcripts, often resulting in highly potent down-regulation of gene expression.
Genzyme, Alnylam partner to develop and commercialize RNAi therapeutics against ATTR

Genzyme, Alnylam partner to develop and commercialize RNAi therapeutics against ATTR

U.S. District Court rules in favor of Alnylam in patent infringement case against Tekmira

U.S. District Court rules in favor of Alnylam in patent infringement case against Tekmira

Recent data from Silence Therapeutics’ Atu111 pre-clinical study on acute lung injury

Recent data from Silence Therapeutics’ Atu111 pre-clinical study on acute lung injury

Alnylam announces complete results from ALN-RSV01 Phase IIb trial on RSV infection

Alnylam announces complete results from ALN-RSV01 Phase IIb trial on RSV infection

New results describe development of DC cancer vaccine with enhanced immunogenic potential

New results describe development of DC cancer vaccine with enhanced immunogenic potential

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Positive results from Alnylam’s ALN-TTR02 Phase I trial on TTR-mediated amyloidosis

Positive results from Alnylam’s ALN-TTR02 Phase I trial on TTR-mediated amyloidosis

New paper documents discovery of novel lipids, including MC3

New paper documents discovery of novel lipids, including MC3

FDA provides Orphan Drug Designation to Alnylam’s ALN-TTR02

FDA provides Orphan Drug Designation to Alnylam’s ALN-TTR02

Alnylam announces results from ALN-VSP Phase I study on liver cancers

Alnylam announces results from ALN-VSP Phase I study on liver cancers

Top-line results from Alnylam’s ALN-RSV01 Phase IIb trial on RSV infection

Top-line results from Alnylam’s ALN-RSV01 Phase IIb trial on RSV infection

Final results from Alnylam’s ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Final results from Alnylam’s ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Alnylam first quarter revenues decrease to $20.6 million

Alnylam first quarter revenues decrease to $20.6 million

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

Arrowhead, Axolabs enter into RNAi therapeutics strategic agreement

Arrowhead, Axolabs enter into RNAi therapeutics strategic agreement

Alnylam commences underwritten public offering of 7,000,000 shares of common stock

Alnylam commences underwritten public offering of 7,000,000 shares of common stock

New cERD method can detect RNAi activity in biological fluids

New cERD method can detect RNAi activity in biological fluids

Alnylam receives U.S. patent allowance for LNP platform

Alnylam receives U.S. patent allowance for LNP platform

Alnylam sues Tekmira over LNP-formulated siRNA molecules

Alnylam sues Tekmira over LNP-formulated siRNA molecules